Related Experiment Video

Updated: Mar 7, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma

Rosie Elizabeth Ann Gutteridge1, Chandra K Singh1, Mary Ann Ndiaye1

  • 1Department of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.

Cancer Letters
|February 26, 2017
PubMed

Insights

Polo-like kinase 1 (PLK1) influences melanoma cell metabolism by altering key metabolic genes. PLK1 inhibition upregulates FBP1, suggesting PLK1

Area of Science:

  • Cellular Biology
  • Cancer Research
  • Molecular Oncology

Background:

  • Limited studies suggest a link between polo-like kinase 1 (PLK1) and cellular metabolism.
  • PLK1 is a mitotic kinase with potential roles beyond cell division.

Purpose of the Study:

  • To investigate the role of PLK1 in regulating metabolic gene expression in melanoma cells.
  • To identify specific metabolic pathways and genes modulated by PLK1 activity.

Main Methods:

  • Utilized inducible RNA interference in A375 melanoma cells.
  • Employed PCR array and multiple validation techniques for gene expression analysis.
  • Performed Ingenuity Pathway Analysis (IPA) and in vivo xenograft studies with PLK1 inhibitor BI 6727.

Main Results:

  • PLK1 knockdown significantly downregulated IDH1, PDP2, and PCK1, while upregulating FBP1.
  • IPA identified glycolysis and pentose phosphate pathway as major canonical pathways affected by PLK1.
  • Inhibition of PLK1 in vivo and in melanoma cells led to FBP1 upregulation and PCK1 downregulation, with an inverse correlation observed between PLK1 and FBP1 expression.
  • FBP1 was found to be significantly downregulated in a panel of melanoma cells.

Conclusions:

  • PLK1 plays a significant role in modulating metabolic gene expression in melanoma.
  • PLK1 may function as a key regulator of metabolic homeostasis in melanoma cells.
  • FBP1 emerges as a critical modulator of proliferation and a potential target in PLK1-mediated metabolic alterations.
Keywords:
MelanomaMetabolismPolo like kinase

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K